TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma.
Smad-signaling pathway
TGF-β
epithelial-to-mesenchymal transition
inhibition
renal cell carcinoma
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
19 Feb 2019
19 Feb 2019
Historique:
received:
21
09
2018
accepted:
01
02
2019
entrez:
14
3
2019
pubmed:
14
3
2019
medline:
14
3
2019
Statut:
epublish
Résumé
Epithelial-to-mesenchymal transition (EMT) is a crucial step in cancer progression and the number one reason for poor prognosis and worse overall survival of patients. Although this essential process has been widely studied in many solid tumors as e.g. melanoma and breast cancer, more detailed research in renal cell carcinoma (RCC) is required, especially for the major EMT-inducer transforming growth factor beta (TGF-β). Here, we provide a study of six different RCC cell lines of two different RCC subtypes and their response to recombinant TGF-β1 treatment. We established a model system shifting the cells to a mesenchymal cell type without losing their mesenchymal character even in the absence of the external stimulus. This model system forms a solid basis for future studies of the EMT process in RCCs to better understand the molecular basis of this process responsible for cancer progression.
Identifiants
pubmed: 30863498
doi: 10.18632/oncotarget.26682
pii: 26682
pmc: PMC6407676
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1507-1524Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST All authors declare no conflict of interest.
Références
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Nature. 2001 May 17;411(6835):349-54
pubmed: 11357142
Clin Cancer Res. 2001 Oct;7(10):3113-9
pubmed: 11595703
J Cell Sci. 2002 Sep 1;115(Pt 17):3355-6
pubmed: 12154066
Cancer Res. 2003 Jul 15;63(14):4107-11
pubmed: 12874014
Genomics. 2003 Sep;82(3):365-77
pubmed: 12906861
Cell. 1992 Dec 11;71(6):1003-14
pubmed: 1333888
J Urol. 2004 Feb;171(2 Pt 1):885-9
pubmed: 14713847
Cancer Res. 2005 Mar 15;65(6):2296-302
pubmed: 15781643
Respir Res. 2005 Jun 09;6:56
pubmed: 15946381
Blood. 2006 Mar 1;107(5):2013-21
pubmed: 16278308
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
Kidney Int. 2008 Sep;74(5):560-5
pubmed: 18596735
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Cancer Res. 2009 Feb 15;69(4):1561-9
pubmed: 19190330
Int J Mol Med. 2009 Mar;23(3):307-11
pubmed: 19212647
Biochim Biophys Acta. 2009 Jul;1793(7):1165-73
pubmed: 19339207
Int J Urol. 2009 May;16(5):432-43
pubmed: 19453547
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Clin Invest. 2009 Jun;119(6):1429-37
pubmed: 19487819
Eur J Immunol. 2009 Jul;39(7):1754-64
pubmed: 19544488
Gastroenterology. 2010 Apr;138(4):1406-17
pubmed: 20026115
Cancer Res. 2010 Jan 15;70(2):752-61
pubmed: 20068166
Anal Cell Pathol (Amst). 2010;33(3):121-32
pubmed: 20978319
Cells Tissues Organs. 2011;193(1-2):85-97
pubmed: 21051862
Int Arch Allergy Immunol. 2011;155(2):119-28
pubmed: 21196756
Clin Exp Metastasis. 2011 Apr;28(4):351-66
pubmed: 21374085
Dev Dyn. 2011 Jun;240(6):1502-11
pubmed: 21412939
Exp Biol Med (Maywood). 2011 May 1;236(5):537-45
pubmed: 21427233
J Immunol. 2011 May 1;186(9):5021-3
pubmed: 21505213
Immunity. 2011 May 27;34(5):729-40
pubmed: 21530327
Cancer Immunol Immunother. 2011 Aug;60(8):1181-93
pubmed: 21688178
Lab Invest. 2011 Oct;91(10):1443-58
pubmed: 21808237
Cell Cycle. 2011 Sep 1;10(17):2865-73
pubmed: 21862874
Cancer Microenviron. 2012 Apr;5(1):19-28
pubmed: 21892699
Virchows Arch. 2011 Nov;459(5):465-75
pubmed: 21997759
Front Biosci (Schol Ed). 2012 Jan 01;4:671-84
pubmed: 22202084
Oncologist. 2012;17(1):46-54
pubmed: 22234634
Semin Cancer Biol. 2012 Oct;22(5-6):446-54
pubmed: 22548724
Mol Cancer Res. 2012 Aug;10(8):1109-19
pubmed: 22707636
FEBS Lett. 2012 Jul 4;586(14):1959-70
pubmed: 22710176
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
J Hum Genet. 2013 Aug;58(8):508-16
pubmed: 23635949
Ann Dermatol. 2013 May;25(2):135-44
pubmed: 23717002
J Immunol. 2013 Aug 1;191(3):1486-95
pubmed: 23817426
Cancer Lett. 2013 Nov 28;341(1):41-5
pubmed: 23973264
Mol Cancer Res. 2013 Nov;11(11):1462-77
pubmed: 24025972
Cell Signal. 2013 Dec;25(12):2856-62
pubmed: 24044921
Cancer Sci. 2013 Dec;104(12):1609-17
pubmed: 24112779
Clin Cancer Res. 2014 Apr 1;20(7):1779-90
pubmed: 24486593
Mol Clin Oncol. 2013 Jan;1(1):3-11
pubmed: 24649114
PLoS One. 2014 Jul 15;9(7):e102041
pubmed: 25025131
Cancer Cell. 2014 Sep 8;26(3):319-330
pubmed: 25155756
Ann Oncol. 2014 Sep;25 Suppl 3:iii49-56
pubmed: 25210086
Carcinogenesis. 2014 Nov;35(11):2602-10
pubmed: 25233932
Sci Signal. 2014 Sep 23;7(344):re8
pubmed: 25249658
Sci Signal. 2014 Sep 30;7(345):ra91
pubmed: 25270257
Oncol Lett. 2014 Nov;8(5):2171-2174
pubmed: 25295105
J Cell Physiol. 2015 Aug;230(8):1916-28
pubmed: 25546616
Front Oncol. 2015 Jan 26;5:3
pubmed: 25674539
Oncotarget. 2015 May 10;6(13):11395-406
pubmed: 25890500
Mol Cancer Res. 2015 Aug;13(8):1248-62
pubmed: 25934695
Oncotarget. 2015 May 30;6(15):13371-86
pubmed: 25945836
Radiol Bras. 2015 May-Jun;48(3):166-74
pubmed: 26185343
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Tumour Biol. 2016 Jan;37(1):115-25
pubmed: 26563372
Mol Diagn Ther. 2016 Apr;20(2):111-7
pubmed: 26940073
Oncotarget. 2016 Jun 14;7(24):35917-35931
pubmed: 27166254
J Immunol. 2016 Aug 1;197(3):691-8
pubmed: 27431984
Sci Rep. 2017 Feb 14;7:41670
pubmed: 28195144
Oncotarget. 2017 Dec 8;8(69):113502-113515
pubmed: 29371925
Ann Diagn Pathol. 2018 Jun;34:89-93
pubmed: 29661736
J Immunol. 1986 Aug 15;137(4):1270-4
pubmed: 3525675
J Urol. 1995 Jul;154(1):28-31
pubmed: 7776446
Nature. 1994 Aug 4;370(6488):341-7
pubmed: 8047140
Cancer Res. 1996 Apr 15;56(8):1756-60
pubmed: 8620489
Acta Anat (Basel). 1995;154(1):8-20
pubmed: 8714286
J Biol Chem. 1997 Oct 31;272(44):28107-15
pubmed: 9346966
Eur J Immunol. 1998 Jan;28(1):122-33
pubmed: 9485192
J Neurooncol. 1998 Jan;36(2):123-40
pubmed: 9525812